Diagnosis and treatment of peripheral T-cell lymphomas: Update recommendations of the Belgian Hematology Society (BHS)

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive diseases associated with poor outcomes. Recent progress in understanding of the biology and pathogenesis based on molecular profiling and next-generation sequencing has led to the introduction of new provisional entities in the World Health Organization (WHO) classification system of 2017 and to the emergence of new drugs.1 Previous Belgian guidelines were published in 2013.2 This review will discuss the diagnosis, work-up and treatment of PTCL including these advances as well as the limitation of the availability of drug... Mehr ...

Volltext
Verfasser: Wolfromm, A
Bailly, S
Van Den Neste, E
André, Marc
Saevels, K
Antoine Poirel, H
Tousseyn, T
Van Hende, V
Snauwaert, S
Janssens, A
Jacquy, C
Bonnet, C
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Verlag/Hrsg.: Ariez International BV
Schlagwörter: Anaplastic large-cell lymphoma / angioimmunoblastic T-cell lymphoma / autologous stem cell transplantation / BV-CHP / peripheral T-cell lymphoma / peripheral T-cell lymphoma not otherwise specified
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26495758
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/260263

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive diseases associated with poor outcomes. Recent progress in understanding of the biology and pathogenesis based on molecular profiling and next-generation sequencing has led to the introduction of new provisional entities in the World Health Organization (WHO) classification system of 2017 and to the emergence of new drugs.1 Previous Belgian guidelines were published in 2013.2 This review will discuss the diagnosis, work-up and treatment of PTCL including these advances as well as the limitation of the availability of drugs according to the Belgian reimbursement rules.